|
|
乳腺癌内分泌治疗伴随疾病之代谢相关脂肪性肝病的防治研究进展
|
Abstract:
乳腺癌是女性最常见的恶性肿瘤，治疗方式除传统手术、放疗和化疗外，内分泌治疗也是乳腺癌综合治疗的重要手段。通常内分泌治疗周期较长，容易导致机体代谢紊乱，诱发脂肪性肝病。代谢相关脂肪性肝病(MAFLD)的发病率逐年攀升，现已成为全球最常见的慢性肝病，同时也是乳腺癌内分泌治疗随访期间常见的并发症之一，不仅可能引起慢性肝损伤和肝纤维化，严重时甚至发展为肝硬化和肝癌，对患者的生活质量和预后造成显著的负面影响。然而，目前对乳腺癌群体中MAFLD的认识和防治尚未引起重视。本文旨在阐述乳腺癌内分泌治疗并发症之一，即MAFLD的防治研究进展，包括其发病因素、诊断方式及防治策略，以期加强该类疾病的早期预防与精准诊治，达到进一步提高患者的生活质量并改善预后的目标。
Breast cancer is the most common malignant tumor in women. In addition to traditional surgery, radiotherapy and chemotherapy, endocrine therapy is also an important means of comprehensive treatment for breast cancer. However, endocrine therapy usually has a long duration, leading to metabolic disorders and increasing the risk of fatty liver disease. The incidence of metabolic-associated fatty liver disease (MAFLD) is rising annually, which has become one of the most common chronic liver diseases globally. It is also a common complication during the follow-up of endocrine therapy for breast cancer. MAFLD can not only cause chronic liver injury and liver fibrosis, but in severe cases, it may even progress to liver cirrhosis and liver cancer, significantly and negatively impacting patients’ quality of life and prognosis. Nevertheless, currently, the awareness and prevention-treatment measures for MAFLD in the breast cancer population have not received sufficient attention. The aim of this review is to clarify the advancements in the prevention and treatment of MAFLD, one of the complications of breast cancer endocrine therapy, covering its etiological factors, diagnostic approaches, and therapeutic strategies. The ultimate goal is to enhance the early prevention and precise diagnosis and treatment of this type of disease, so as to further improve patients’ quality of life and prognosis.
| [1] | Sun, K., Zhang, B., Lei, S., Zheng, R., Liang, X., Li, L., et al. (2024) Incidence, Mortality, and Disability-Adjusted Life Years of Female Breast Cancer in China, 2022. Chinese Medical Journal, 137, 2429-2436. https://doi.org/10.1097/cm9.0000000000003278 |
| [2] | 中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范(2024年版) [J]. 中国癌症杂志, 2023, 33(12): 1092-1187. |
| [3] | Huppert, L.A., Gumusay, O., Idossa, D. and Rugo, H.S. (2023) Systemic Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Early Stage and Metastatic Breast Cancer. CA: A Cancer Journal for Clinicians, 73, 480-515. https://doi.org/10.3322/caac.21777 |
| [4] | 江泽飞. 乳腺癌内分泌治疗专家共识(2023版) [J]. 中华医学杂志, 2023, 103(38): 2993-3001. |
| [5] | 田申, 伍娟, 孔令泉, 等. 关注乳腺癌伴随疾病全方位管理之非酒精性脂肪性肝病的管理[J]. 中国临床新医学, 2020, 13(8): 836-840. |
| [6] | 李浩, 罗欢, 孔令泉, 等. 乳腺癌伴随疾病全方位管理之内分泌代谢性疾病管理[J]. 中国临床新医学, 2019, 12(2): 111-116. |
| [7] | 孙明芳, 谢晓冬. 化疗及内分泌治疗对乳腺癌患者肝脏脂肪变性影响的研究进展[J]. 大连医科大学学报, 2010, 32(3): 352-355. |
| [8] | 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版) [J]. 中华肝脏病杂志, 2024, 32(5): 418-434. |
| [9] | Eslam, M., Newsome, P.N., Sarin, S.K., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. |
| [10] | 孔令泉, 田申, 徐周, 等. 关注乳腺癌患者代谢相关脂肪性肝病的诊治[J]. 中华内分泌外科杂志, 2022, 16(5): 520-524. |
| [11] | Tian, S., Li, H., Li, R., Ran, L., Li, S., Wu, J., et al. (2022) Prevalence of Hepatic Steatosis and Metabolic Associated Fatty Liver Disease among Female Breast Cancer Survivors. Chinese Medical Journal, 135, 2372-2374. https://doi.org/10.1097/cm9.0000000000002121 |
| [12] | Lonardo, A., Byrne, C.D., Caldwell, S.H., Cortez‐Pinto, H. and Targher, G. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease: Meta‐Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 1388-1389. https://doi.org/10.1002/hep.28584 |
| [13] | Powell, E.E., Wong, V.W. and Rinella, M. (2021) Non-Alcoholic Fatty Liver Disease. The Lancet, 397, 2212-2224. https://doi.org/10.1016/s0140-6736(20)32511-3 |
| [14] | Paik, J.M., Golabi, P., Younossi, Y., Mishra, A. and Younossi, Z.M. (2020) Changes in the Global Burden of Chronic Liver Diseases from 2012 to 2017: The Growing Impact of NAFLD. Hepatology, 72, 1605-1616. https://doi.org/10.1002/hep.31173 |
| [15] | Tian, H., Zhang, K., Hui, Z., Ren, F., Ma, Y., Han, F., et al. (2023) Global Burden of Non-Alcoholic Fatty Liver Disease in 204 Countries and Territories from 1990 to 2019. Clinics and Research in Hepatology and Gastroenterology, 47, Article ID: 102068. https://doi.org/10.1016/j.clinre.2022.102068 |
| [16] | Kim, G., Lee, H.C., Choe, J., Kim, M., Lee, M.J., Chang, H., et al. (2018) Association between Non-Alcoholic Fatty Liver Disease and Cancer Incidence Rate. Journal of Hepatology, 68, 140-146. https://doi.org/10.1016/j.jhep.2017.09.012 |
| [17] | 彭晓林, 张闽光. 非酒精性脂肪肝影像学定性定量检测的研究进展[J]. 现代医学, 2021, 49(8): 981-985. |
| [18] | Chandra Kumar, C.V., Skantha, R. and Chan, W. (2022) Non-Invasive Assessment of Metabolic Dysfunction-Associated Fatty Liver Disease. Therapeutic Advances in Endocrinology and Metabolism, 13, 1-17. https://doi.org/10.1177/20420188221139614 |
| [19] | Hong, N., Yoon, H.G., Seo, D.H., Park, S., Kim, S.I., Sohn, J.H., et al. (2017) Different Patterns in the Risk of Newly Developed Fatty Liver and Lipid Changes with Tamoxifen versus Aromatase Inhibitors in Postmenopausal Women with Early Breast Cancer: A Propensity Score-Matched Cohort Study. European Journal of Cancer, 82, 103-114. https://doi.org/10.1016/j.ejca.2017.05.002 |
| [20] | Yoo, J., Lim, Y.S., Kim, M.S., Lee, B., Kim, B., Kim, Z., et al. (2020) Risk of Fatty Liver after Long-Term Use of Tamoxifen in Patients with Breast Cancer. PLOS ONE, 15, e0236506. https://doi.org/10.1371/journal.pone.0236506 |
| [21] | Kim, H.Y., Lim, W., Moon, B. and Lee, H.A. (2020) Abstract P5-08-14: Characteristics and Risk Factors of Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Breast Cancer Survivors. Cancer Research, 80, P5-08-14. https://doi.org/10.1158/1538-7445.sabcs19-p5-08-14 |
| [22] | 牛小敏, 张晓鹏. 脂肪肝背景下肝转移瘤的CT诊断研究[J]. 肿瘤防治研究, 2004(10): 604-607. |
| [23] | 唐灿, 赵海娜, 彭玉兰, 等. 1例合并脂肪肝的乳腺癌术后肝转移不典型超声表现[J]. 中国介入影像与治疗学, 2024, 21(12): 804-805. |
| [24] | 王海强, 李冰琪, 周千瑶, 等. 雌激素对绝经期女性非酒精性脂肪肝病影响的研究进展[J]. 医学研究杂志, 2023, 52(11): 1-5. |
| [25] | Yang, M., Liu, Q., Huang, T., Tan, W., Qu, L., Chen, T., et al. (2020) Dysfunction of Estrogen-Related Receptor Alpha-Dependent Hepatic VLDL Secretion Contributes to Sex Disparity in NAFLD/NASH Development. Theranostics, 10, 10874-10891. https://doi.org/10.7150/thno.47037 |
| [26] | 李薇. 乳腺癌患者的营养治疗专家共识[J]. 肿瘤代谢与营养电子杂志, 2021, 8(4): 374-379. |
| [27] | Fan, J., Luo, S., Ye, Y., Ju, J., Zhang, Z., Liu, L., et al. (2021) Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in the Contemporary South China Population. Nutrition & Metabolism, 18, 82. https://doi.org/10.1186/s12986-021-00611-x |
| [28] | 国家肿瘤质控中心乳腺癌专家委员会, 北京乳腺病防治学会健康管理专业委员会. 中国乳腺癌随诊随访与健康管理指南(2022版) [J]. 中华肿瘤杂志, 2022, 44(1): 1-28. |
| [29] | 马飞, 徐兵河, 邵志敏, 等. 乳腺癌随访及伴随疾病全方位管理指南[J]. 中华肿瘤杂志, 2019, 41(1): 29-41. |
| [30] | Stavropoulos, K., Imprialos, K., Pittaras, A., Faselis, C., Narayan, P. and Kokkinos, P. (2018) Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Current Vascular Pharmacology, 16, 239-245. https://doi.org/10.2174/1570161115666170621080835 |
| [31] | 陈镜宇, 范建高. 代谢相关脂肪性肝病的危害和饮食治疗对策[J]. 肝脏, 2021, 26(11): 1287-1289. |
| [32] | 范建高. 加强非酒精性脂肪性肝病患者生活方式的管理[J]. 中华健康管理学杂志, 2020, 14(4): 308-312. |
| [33] | 范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版) [J]. 实用肝脏病杂志, 2024, 27(4): 494-510. |
| [34] | Razavizade, M., Jamali, R., Arj, A., Matini, S.M., Moraveji, A. and Taherkhani, E. (2013) The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial. Hepatitis Monthly, 13, e9270. https://doi.org/10.5812/hepatmon.9270 |
| [35] | Guo, W., Tian, W., Lin, L. and Xu, X. (2020) Liraglutide or Insulin Glargine Treatments Improves Hepatic Fat in Obese Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease in Twenty-Six Weeks: A Randomized Placebo-Controlled Trial. Diabetes Research and Clinical Practice, 170, Article ID: 108487. https://doi.org/10.1016/j.diabres.2020.108487 |
| [36] | Taheri, H., Malek, M., Ismail-Beigi, F., Zamani, F., Sohrabi, M., Reza babaei, M., et al. (2020) Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Advances in Therapy, 37, 4697-4708. https://doi.org/10.1007/s12325-020-01498-5 |
| [37] | Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., et al. (2016) Long-Term Pioglitazone Treatment for Patients with Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Annals of Internal Medicine, 165, 305-315. https://doi.org/10.7326/m15-1774 |
| [38] | Boeckmans, J., Natale, A., Rombaut, M., Buyl, K., Rogiers, V., De Kock, J., et al. (2019) Anti-Nash Drug Development Hitches a Lift on PPAR Agonism. Cells, 9, Article No. 37. https://doi.org/10.3390/cells9010037 |
| [39] | Tanaka, N., Mukaiyama, K., Morikawa, A., Kawakami, S., Ichise, Y., Kimura, T., et al. (2021) Pemafibrate, a Novel Selective Pparα Modulator, Attenuates Tamoxifen-Induced Fatty Liver Disease. Clinical Journal of Gastroenterology, 14, 846-851. https://doi.org/10.1007/s12328-021-01386-7 |
| [40] | 脂肪性肝病诊疗规范化的专家建议(2019年修订版) [J]. 临床肝胆病杂志, 2019, 35(11): 2426-2430. |
| [41] | 徐清扬, 范建高. 肾素-血管紧张素系统抑制剂治疗非酒精性脂肪性肝病的研究进展[J]. 肝脏, 2022, 27(11): 1161-1163. |
| [42] | Cho, Y., Rhee, H., Kim, Y., Lee, M., Lee, B., Kang, E.S., et al. (2022) Ezetimibe Combination Therapy with Statin for Non-Alcoholic Fatty Liver Disease: An Open-Label Randomized Controlled Trial (ESSENTIAL Study). BMC Medicine, 20, Article No. 93. https://doi.org/10.1186/s12916-022-02288-2 |
| [43] | Lee, J.I., Lee, H.W., Lee, K.S., Lee, H.S. and Park, J. (2020) Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. American Journal of Gastroenterology, 116, 116-124. https://doi.org/10.14309/ajg.0000000000000845 |
| [44] | 刘路, 韩涛, 周冷潇. 他汀类药物在肝病防治中的应用[J]. 临床肝胆病杂志, 2017, 33(5): 985-989. |
| [45] | Clare, K., Dillon, J.F. and Brennan, P.N. (2022) Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD. Journal of Clinical and Translational Hepatology, 10, 939-946. https://doi.org/10.14218/jcth.2022.00067 |
| [46] | Usman, M. and Bakhtawar, N. (2020) Vitamin E as an Adjuvant Treatment for Non-Alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials. Cureus, 12, e9018. |
| [47] | Wang, M.Y., Prabahar, K., Găman, M. and Zhang, J.L. (2023) Vitamin E Supplementation in the Treatment on Nonalcoholic Fatty Liver Disease (NAFLD): Evidence from an Umbrella Review of Meta‐Analysis on Randomized Controlled Trials. Journal of Digestive Diseases, 24, 380-389. https://doi.org/10.1111/1751-2980.13210 |
| [48] | Younossi, Z.M., Ratziu, V., Loomba, R., et al. (2019) Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis from a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial. The Lancet, 394, 2184-2196. |
| [49] | 刘素彤, 苏凯奇, 赵晨露, 等. 代谢相关脂肪性肝病的内科治疗进展[J]. 临床肝胆病杂志, 2021, 37(4): 947-950. |
| [50] | Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., et al. (2016) The Severity of Nonalcoholic Fatty Liver Disease Is Associated with Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota. Hepatology, 63, 764-775. https://doi.org/10.1002/hep.28356 |
| [51] | Zhou, X., Wang, J., Zhou, S., Liao, J., Ye, Z. and Mao, L. (2023) Efficacy of Probiotics on Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Medicine, 102, e32734. https://doi.org/10.1097/md.0000000000032734 |
| [52] | Kobyliak, N., Abenavoli, L., Falalyeyeva, T., Mykhalchyshyn, G., Boccuto, L., Kononenko, L., et al. (2018) Beneficial Effects of Probiotic Combination with Omega-3 Fatty Acids in NAFLD: A Randomized Clinical Study. Minerva Medica, 109, 418-428. https://doi.org/10.23736/s0026-4806.18.05845-7 |
| [53] | Famouri, F., Shariat, Z., Hashemipour, M., Keikha, M. and Kelishadi, R. (2017) Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. Journal of Pediatric Gastroenterology and Nutrition, 64, 413-417. https://doi.org/10.1097/mpg.0000000000001422 |
| [54] | Harrison, S.A., Bashir, M.R., Guy, C.D., Zhou, R., Moylan, C.A., Frias, J.P., et al. (2019) Resmetirom (MGL-3196) for the Treatment of Non-Alcoholic Steatohepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Lancet, 394, 2012-2024. https://doi.org/10.1016/s0140-6736(19)32517-6 |
| [55] | Harrison, S.A., Bedossa, P., Guy, C.D., et al. (2024) A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. The New England Journal of Medicine, 390, 497-509. |
| [56] | European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) (2024) EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Journal of Hepatology, 81, 492-542. |
| [57] | 肖倩倩, 王梦雨, 范建高. 亚太肝病研究学会代谢相关脂肪性肝病临床诊疗指南(治疗部分)简介[J]. 临床肝胆病杂志, 2021, 37(1): 41-45. |
| [58] | Lassailly, G., Caiazzo, R., Ntandja-Wandji, L., Gnemmi, V., Baud, G., Verkindt, H., et al. (2020) Bariatric Surgery Provides Long-Term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology, 159, 1290-1301.e5. https://doi.org/10.1053/j.gastro.2020.06.006 |
| [59] | Navarro-Masip, È., Mestres, N., Zorzano-Martínez, M., Salinas-Roca, B., Sánchez, E., López-Cano, C., et al. (2024) Mid-Term Effects of Bariatric Surgery on Metabolic Dysfunction-Associated Fatty Liver Disease Remission and Predictive Factors: A Prospective Study with a Focus on Non-Invasive Diagnosis. Obesity Surgery, 34, 841-849. https://doi.org/10.1007/s11695-024-07071-1 |
| [60] | Aitharaju, V., Ragheb, J., Firkins, S., Patel, R. and Simons-Linares, C.R. (2025) Endoscopic Bariatric and Metabolic Therapies and Its Effect on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review of the Current Literature. Surgery for Obesity and Related Diseases, 21, 175-182. https://doi.org/10.1016/j.soard.2024.09.012 |
| [61] | Adali, G., Bilgic, N.M., Kalaman, A.E., Ozturk, O. and Ozdil, K. (2023) Prevalence and Predictors of Metabolic-Associated Fatty Liver Disease in Liver Transplant Recipients: A Cross-Sectional Prospective Study. Hepatology Forum, 4, 129-134. https://doi.org/10.14744/hf.2023.2023.0032 |
